Form 4: Voyager Therapeutics Director Nancy Vitale Receives 24,000 Stock Options as Part of Compensation

Voyager Therapeutics, Inc. Director Nancy Vitale was granted 24,000 stock options with an exercise price of $3.28, aligning her interests with shareholders.

Summary

• Nancy Vitale, a Director of Voyager Therapeutics, Inc. (VYGR), was granted 24,000 stock options on June 3, 2025.
• The stock options have an exercise price of $3.28 per share.
• These options were issued under the company's 2025 Stock Incentive Plan, in line with its director compensation policy.
• The vesting commencement date for these options is the grant date, June 3, 2025.
• All shares underlying the option will vest upon the earlier of the one-year anniversary of the vesting commencement date or the date of the next annual meeting of stockholders, contingent on Ms. Vitale's continued service as a director.
• The options have an expiration date of June 3, 2035.
• Following this transaction, Nancy Vitale beneficially owns 24,000 derivative securities (stock options) directly.

Sentiment

Score: 7

Explanation: The document reports a routine compensation event for a director, which is generally positive as it aligns management/director interests with shareholders. It does not contain any negative or unexpected information.

Positives

• The grant of stock options to Director Nancy Vitale aligns her financial interests directly with the long-term performance and shareholder value creation of Voyager Therapeutics.
• The issuance is part of a pre-existing 2025 Stock Incentive Plan and director compensation policy, indicating structured and transparent governance regarding executive and director remuneration.

Future Outlook

The stock options are designed to incentivize continued service and align the director's interests with the company's future performance, with vesting contingent on ongoing tenure.

Management Comments

• "This stock option was issued pursuant to the 2025 Stock Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy."
• "The vesting commencement date (the 'Vesting Commencement Date') of the option is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service as a director."

Industry Context

The grant of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of compensation packages designed to attract and retain experienced board members and align their incentives with long-term company success.

Comparison to Industry Standards

• The structure of this option grant, including the vesting schedule tied to continued service and the use of a stock incentive plan, is consistent with standard corporate governance and compensation practices observed across the biotechnology sector.
• While specific comparable companies or projects are not detailed in this filing, the mechanism of equity-based compensation for directors is a widely adopted benchmark for incentivizing leadership in growth-oriented industries like biotech.

Corporate Governance

Related Party Transactions

• The grant of 24,000 stock options to Nancy Vitale, a director, constitutes a related party transaction as it involves compensation from the company to a member of its board of directors. This is a standard and disclosed form of compensation.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's interests with shareholders, potentially leading to better long-term decision-making aimed at increasing share value.
• Employees: While not directly impacted, the existence of a stock incentive plan suggests a broader framework for employee and director compensation that can attract and retain talent.

Next Steps

• The stock options will vest over time, contingent on Nancy Vitale's continued service as a director.
• Nancy Vitale may choose to exercise these options at any point after vesting and before the expiration date, subject to company policy and blackout periods.

Key Dates

Recommendation

Keywords

Voyager Therapeutics, VYGR, Stock Option, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, Beneficial Ownership, Incentive Plan